GlassScriptPhysician profile
Robert A Houghton
NPI 1124138045
$32,095.76
in general payments reported to CMS, 2019-2025
51 companies · $4,117 in 2025
The $4,117 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,687 · 2020: $3,571 · 2021: $5,445 · 2022: $4,604 · 2023: $5,103 · 2024: $4,569 · 2025: $4,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,777.46 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,695.40 | 2019-2025 | Descovy, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $7,952.49 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,926.21 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,642.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,228.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,129.29 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $1,051.43 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $927.28 | 2019-2024 | Livalo |
| Pfizer INC. | $854.88 | 2019-2025 | |
| Emd Serono, INC. | $796.59 | 2019-2025 | Serostim, Serostim |
| Theratechnologies INC. | $735.49 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Products, LP | $720.03 | 2019-2022 | |
| Lilly USA, LLC | $398.51 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $357.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.29 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Houghton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.